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 Introduction 
Acute kidney injury (AKI) represents a very important and potentially devastating 
disorder in clinical medicine.  The incidence of AKI is increasing to epidemic 
proportions.  AKI is associated with prolonged hospital stay, increased healthcare 
costs and high mortality in critically ill patients. Serum creatinine does not function well 
to predict AKI early enough to do early intervention, which is the primary impetus for 
the discovery of novel AKI biomarkers. The goal of most AKI biomarker research has 
been the discovery of a sensitive and specific early biomarker of renal injury.   
Recently, several new AKI biomarkers have been developed to facilitate early 
detection, differential diagnosis, and prognosis, and which include neutrophil 
gelatinase-associated lipocalin (NGAL)1-4, kidney injury molecule 1 (KIM-1)5-7, 
interleukin 18 (IL-18)8,9 and liver-type fatty acid-binding protein (L-FABP)10-12.   
Activin is a multifunctional cytokine belonging to the TGF-β superfamily that 
regulates the growth and differentiation of cells in various organs13.  Its action is 
modulated by an endogenous activin antagonist, follistatin14. Activin signals are 
mediated by two types of cell surface serine/threonine receptors.  Activin first binds to 
the type II receptor (ActRII or ActRIIB), which leads to recruitment and phosphorylation 
of the type I receptor (ActRI or ActRIB) and formation of receptor complexes.  The 
activated type I receptor then phosphorylates Smad proteins, which are subsequently 
translocated to the nucleus and regulate target gene expression15.  Activin A is 
expressed in the developing stage of the kidney16.   Organ culture experiments 
demonstrated that activin A inhibits branching morphogenesis of ureteric buds17-19 as 
well as ureteric bud budding from the Wolffian duct20.  In an in vitro tubulogenesis 
model using Madin-Darby canine kidney (MDCK) cells, activin A tonically inhibited 
branching tubulogenesis.  On the other hand, blockade of endogenous activin A 
action by follistatin induced branching tubulogenesis21, suggesting that activin A 
negatively regulates tubulogenesis during kidney organogenesis22,23. 
Previously, we demonstrated that activin A expression was significantly increased 
in tubular cells of the kidney after renal ischemia in rats. Furthermore, intravenously 
 administered follistatin, which binds to activins and block their actions, improved renal 
dysfunction and histological changes after renal ischemia24,25.  We also demonstrated 
that activin A acts as an autocrine inhibitor of cell growth as well as an inducer of 
apoptosis in cultured proximal tubular cells26, suggesting that activin A negatively 
regulates tubular repair of the kidney after AKI.   
In the present study, we demonstrated the presence of activin A in the urine of 
mice with renal ischemia-reperfusion injury.  Activin A expression was markedly 
upregulated in proximal tubular cells of ischemic kidneys.  Urinary activin A level was 
correlated with the degree of tubular damage. Urinary activin A was also significantly 
increased in patients with renal AKI, but not with pre-renal AKI, suggesting that urinary 
activin A might serve as a sensitive biomarker reflecting AKI severity. 
 
  
 Materials and Methods 
Experimental Protocols  
Eight or twelve-week-old male C57BL/6j mice (Japan Charles River, Yokohama, 
Japan) were housed under specific pathogen-free conditions and provided with 
autoclaved food and sterile water ad libitum.  Ischemia reperfusion injury and volume 
depletion were induced in mice as described below.  All animal experiments were 
performed in accordance with Fundamental Guidelines for Proper Conduct of Animal 
Experiment and Related Activities in Academic Research Institutions and were 
approved by the Ethics Review Committee for Animal Experimentation of Gunma 
University (approval number 12-067). 
 
Ischemia reperfusion injury 
Ischemia reperfusion injury was induced in mice as described below.  Briefly, the 
mice were anesthetized with pentobarbital sodium (50 mg/kg) by intraperitoneal 
injection.  Shortly thereafter, buprenorphine (50 μg/kg) was administered 
subcutaneously to control pain and distress.  After deep anesthesia, the abdominal 
cavity was exposed via a midline incision.  Renal ischemia was induced by clamping 
both renal arteries for 15, 22, 25 or 30 min using a non-traumatic vascular clamp.  
Core body temperature was maintained at 37°C by placing the animal on a 
homoeothermic table.  After the ischemia periods indicated above, the clamps were 
removed and reperfusion of the kidneys was confirmed visually.  The mice were 
subsequently sacrificed after various post-ischemic periods.  The kidneys were 
removed and frozen for RNA extraction or fixed in 10% formalin for routine paraffin 
embedding and sectioning for histologic analysis.  Urine was collected from individual 
mice housed in metabolic cages.  After centrifugation at 10,000 rpm for 5 min, all urine 
samples were stored at -80°C until the day of analysis.  
 
Volume depletion models 
To mimic pre-renal AKI, simple volume depletion was induced in mice by water 
 intake restriction.  The degree of dehydration was evaluated by measurement of body 
weight recorded every 24 hr.  Urine and blood samples were collected at 48 hr after 
initiation of water restriction and then mice were sacrificed. 
 
Materials  
Primary antibodies used in this study were as follows: rabbit anti-inhibin beta A 
antibody (ab97705) (Abcam, Cambridge, UK), mouse anti-neutrophil gelatinase-
associated lipocalin (NGAL) antibody (AF1857), mouse anti-kidney injury molecule-1 
(KIM-1) antibody (AF 1817) (R&D Systems, Minneapolis, MN), goat anti-aquaporin 2 
antibody (sc-9882), goat anti-Tamm-Horsfall-protein antibody (sc-19554), mouse anti-
E-cadherin antibody (sc-8426), goat anti-proliferating cell nuclear antigen (PCNA) 
antibody (sc-9857) (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-cleaved 
caspase-3 antibody (#9661; Cell Signaling Technology, Danvers, MA).  Fluorescein 
lotus tetragonolobus lectin (LTL) (FL-1321) was from VECTOR Laboratories 
(Burlingame, CA). 
 
In Situ Hybridization 
 In situ hybridization was performed using a InHyb In Situ Hybridization Kit 
(BioChain Institute Inc., Newark, CA).  Hybridization probes were obtained from 
Genostaff Co. Ltd (Tokyo, Japan).  After deparaffinization and rehydration, sections 
were fixed in 4% paraformaldehyde in DEPC-PBS at room temperature for 20 min.  
After digestion with 10 μg/ml proteinase K at 37°C for 20 min, sections were postfixed 
in 4% paraformaldehyde in DEPC-PBS at room temperature for 15 min.  Sections 
were incubated with pre-hybridization solution for 3 hr at 50°C. Hybridization was 
performed with sense or antisense probes (2.5 ng/μl) at 50°C for 16 hr.  After 
hybridization, sections were washed once in 2 × SSC at 45°C for 10 min, 1.5 × SSC 
45°C for 10 min, and washed twice in 0.2 × SSC at 37°C for 20 min.  Sections were 
incubated in 1× blocking solution for 60 min at room temperature and then incubated 
in a 1:200 diluted solution of AP-conjugated anti-digoxingenin antibody for 1 hr, before 
 washing and detection of the label with nitroblue tetrazolium chloride and 5-bromo-4-
chloro-3-indolyphosphate. 
Real-time PCR 
Tissues were homogenized using a microhomogenizer and total RNA was 
extracted using RNAiso (Takara). First-strand cDNA was made from total RNA using 
SuperScript III First-strand (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. Real-time PCR was performed using the ABI 7300 Real-time PCR System 
(Applied Biosystems, Foster City, CA).  Reactions included 5 μl of a SYBR Green 
Real-time PCR Master Mix (TOYOBO, Osaka, Japan), 0.2 μl of 3’ primer, 0.2 μl of 5’ 
primer, and 1 μl of cDNA.  Samples were incubated at 50°C for 2 min, then at 95°C 
for 1 min, followed by 35 cycles of 15 sec at 95°C, 15 sec at 62°C and 60 sec at 72°C.  
The expression of each gene was quantified in separate tubes with the following 
primers; mouse inhibin βA (143 bp) sense 5’-GATCATCACCTTTGCCGAGT-3’, 
antisense 5’-TGGTCCTGGTTCTGTTAGCC-3’; and mouse GAPDH (460 bp) sense, 
5’-TGCTGAGTATGTCGTGGAGTCTA-3%’, antisense 5’- 
AGTGGGAGTTGCTGTTGAAATC-3’. Data was expressed as the relative expression 
normalized to GAPDH.  Agarose gel electrophoresis of the PCR products after 
quantification by real-time PCR showed single bands of the expected size (data not 
shown).  
 
Renal Function and Urinary Protein 
Serum or urinary creatinine and blood urea nitrogen (BUN) levels were 
assessed using a Hitachi 7180 autoanalyzer (Hitachi High-Technologies, Tokyo, 
Japan).  Urinary protein was measured using a BCA assay kit (Pierce, Rockford, IL, 
USA).  
 
Immunohistochemical Analysis 
 Immunostaining was performed using a VECTASTAIN ABC-kit (Vector 
Laboratories) as described previously24.  Briefly, paraffin-embedded sections (4 μm) 
 were deparaffinized, hydrated according to standard methods, soaked in blocking 
serum, and incubated with primary antibody overnight at 4°C.  After washing with 
phosphate-buffered saline (PBS), sections were incubated with peroxidase-conjugated 
secondary antibody followed by diaminobenzidine and were counterstained with 
periodic acid-Schiff (PAS).  Indirect fluorescent immunostaining was performed as 
follows25.  Briefly, sections were incubated with fluorescein-labeled secondary 
antibodies (Alexa; Molecular Probes, Eugene, OR) and 4’,6’-diamidino-2’-phenylindole 
dihyrochloride (DAPI).  Fluorescent images were recorded with the BZ-X700 all-in-
one fluorescence microscope (KEYENSE, Osaka, Japan).  For the immunostaining 
control, the primary antibody was replaced with PBS, which did not show positive 
staining, confirming specificity. Primary antibodies used in this study were shown in 
above. 
Quantification of activin A-positive areas was performed by measurement of 
positive area in five randomly selected fields of the outer medulla at ×200 magnification 
using Image J software (National Institutes of Health, Bethesda, MD). 
 
Histological Examination 
 PAS-stained sections were microscopically examined at the indicated periods 
after reperfusion. The changes observed were limited to the outer medulla, where 
tubular damage is most obvious, and were graded as follows: 0, normal; 1, areas of 
tubular dilation, necrosis, hemorrhage, and cell desquamation involving <20% of the 
fields; 2, similar changes involving >20% but <40% of the fields; 3, similar changes 
involving >40% but <60% of the fields; 4, similar changes involving >60% of the fields.  
Five sections per mouse were used for analysis.  
 
Terminal Deoxynucleotidyl Transferase-Mediated dUTP-Nick-End-Labeling 
For identification of nuclei with DNA strand breaks at the cellular level, the 
terminal deoxynucleotidyl transferase-mediated dUTP-nick-end-labeling (TUNEL) 
method was performed using an apoptosis in situ detection kit (Takara, Tokyo, Japan) 
 according to the manufacturer’s instructions.  
 
ELISA 
Urinary and serum human/mouse activin A, urinary human/mouse KIM-1 (R&D 
Systems), and urinary mouse NGAL (BIOPORTO, Hellerup, Denmark) was measured 
by ELISA according to the manufacturer’s instructions.    
 
Patients  
Patients who were admitted to Gunma University Hospital for the diagnosis and 
treatment of AKI (n=18) were enrolled. Informed consent was obtained from all 
participants.  This study was approved by the ethical committee on human research 
of Gunma University Graduate School of Medicine (approved number 855).  Urine 
and serum were collected from patients with renal AKI (n=13, drug-induced, 
hypercalcemia, rhabdomyolysis, and cast nephropathy) and pre-renal AKI (n=5, 
dehydration, sepsis, and shock) when the diagnosis was made or following recovery 
from AKI.   
 
Statistical analysis 
Statistical analysis was performed using SPSS Statistics 24 (Chicago, IL).  The 
significance of differences between means was compared using a t-test. When 
comparing the means of more than two variables, data were analyzed using Kruskal-
Wallis test followed by the Mann-Whitney U test using Bonferroni correlation to adjust 
the probability. Correlation was analyzed with Spearman‘s rank correlation test 
coefficients. P<0.05 was considered significant.  
 
 
 
 
 
  
 
Results 
Expression of  βA subunit for Activin A in the Kidneys of Mice after Renal 
Ischemia  
To examine whether activin A is expressed in ischemic kidneys, we first analyzed 
the mRNA expression of βA subunit for activin A in the kidneys of mice after renal 
ischemia for 25 min using real-time PCR (Fig. 1A).  The expression of βA subunit 
mRNA, which was almost undetectable in normal kidneys, was significantly increased 
in ischemic kidneys and peaked at 24 hr after reperfusion.  Next, we examined the 
localization of βA subunit mRNA in normal and ischemic kidneys by in situ hybridization 
(Fig. 1B).  Hybridization signals were not observed in normal kidneys and ischemic 
kidneys at 3 hr after reperfusion.  In contrast, strong hybridization signals for βA 
subunit mRNA was observed, mainly in tubular cells of the outer medulla of the 
ischemic kidneys, at 6 hr after reperfusion and thereafter.  There were no 
hybridization signals in the glomeruli of the ischemic kidneys.  A control experiment 
using a sense probe showed no hybridization signal. 
Localization of activin A was also examined by immunostaining (Fig. 1C).  
Activin A was detected in tubular cells of the cortex and outer medulla of ischemic 
kidneys, but not in normal kidneys. Activin A protein was localized in the cytoplasm of 
LTL-positive proximal tubular cells at 6 hr after reperfusion (Fig. 1D).  At the later 
phase of AKI (120 hr after reperfusion), there were many activin A-positive casts in the 
lumen of renal tubules (Fig. 1D).  Double-staining with several nephron markers 
showed that activin A was localized in LTL-positive proximal tubular cells and the THP-
positive ascending limb of loop of Henle in ischemic kidneys at 48 hr after reperfusion, 
but not in E-cadherin-positive distal tubular cells and AQP2-positive collecting ducts 
(Fig. 1E). 
We further compared the localization of activin A and other AKI biomarkers, such 
as NGAL and KIM-1, in the kidney after renal ischemia for 25 min.  NGAL was present 
 in tubular cells of the ischemic kidneys at 6 to 72 hr after reperfusion.  Activin A was 
partly co-localized with NGAL in the ischemic kidneys (Fig. 2A).  KIM-1 was also 
present in tubular cells of the ischemic kidneys.  Co-localization of activin A and KIM-
1 was observed in the ischemic kidneys at 24 hr after reperfusion and thereafter (Fig. 
2B). 
To characterize activin A-producing cells, we examined the localization of PCNA-
positive proliferating cells in the kidney after renal ischemia (Fig. 2C).  Many PCNA-
positive cells were observed in the ischemic kidneys at 48 hr after reperfusion, but 
none were co-localized with activin A.  There were many apoptotic cells positive for 
TUNEL or active caspase-3 in the ischemic kidneys.  However, activin A-positive cells 
were TUNEL-negative (Fig. 2D) or active caspase-3-negative (Fig. 2E).  These 
results suggest that the regulation of activin A expression was not associated with cell 
proliferation or apoptosis during tubular regeneration after injury. 
 
Detection of Activin A in the Urine of Mice with Ischemia-Reperfusion Injury  
We next examined whether urinary activin A was detectable in mice with AKI.  
Renal ischemia for 22 min was induced in mice and urine was collected for analysis at 
the indicated periods after reperfusion.  Urinary activin A was measured by ELISA.  
Activin A was absent in the urine of normal mice; in contrast, activin A was detected in 
the urine of ischemic mice and a bimodal peak was observed at 3 and 48 hr after renal 
ischemia (Fig. 3A).  
Next, we examined the correlation of urinary activin A with other parameters, such 
as serum creatinine (Fig. 3B), serum activin A (Fig. 3C), urinary NGAL (Fig. 3D), and 
urinary KIM-1 (Fig. 3E).  Urinary activin A was not correlated with any of these 
parameters.  Moreover, there was no significant correlation between serum activin A 
and serum creatinine (Fig. 3F).   
 
Correlation of Urinary Activin A Level with Severity of AKI 
 We then examined the correlation of urinary activin A with the severity of kidney 
 damage.  Mild (15 min), moderate (22 min), and severe (30 min) renal ischemia was 
induced in C57BL/6j mice. Serum, urine and kidney tissues were collected at 48 hr 
after reperfusion.   Immunostaining showed that activin A was detected in the 
ischemic kidneys regardless of ischemic periods (Fig. 4A). BUN, serum creatinine and 
ATN score significantly increased in mice with renal ischemia for 22 and 30 min, but 
not for 15 min (Fig. 4B-4D).  Quantitative analysis demonstrated that activin A-positive 
area significantly increased in the kidneys of mice with renal ischemia for 22 and 30 
min, but not for 15 min (Fig. 4E). Urinary activin A level was significantly increased in 
mice with renal ischemia at 48 hr after reperfusion regardless of ischemic period (Fig. 
4F). 
We examined the correlation between ATN score, activin A-positive area, and 
urinary activin A. There was no significant correlation between ATN score and activin 
A-positive area (Fig. 4G).  Urinary activin A was significantly correlated with activin A-
positive area (Fig. 4H), but there was no correlation between urinary activin A and ATN 
score (Fig. 4I). 
 
Urinary Activin A Level in Patients with Acute Kidney Injury 
We also analyzed urinary activin A in eighteen patients with renal AKI and pre-
renal AKI.  The baseline characteristics of patients are shown in Table 1.  Similar to 
the mouse AKI model described above, urinary activin A was significantly increased in 
renal AKI patients, but was not detected in healthy controls or in pre-renal AKI patients 
(Fig. 5A).  Urinary KIM-1 also increased significantly in patients with renal AKI, but not 
with pre-renal AKI (Fig. 5B). To predict renal AKI patients from non-AKI, the area under 
the receiver-operating characteristic curve was 0.923, sensitivity was 0.846, specificity 
was 1.00, positive predictive value was 1.00 and negative predictive value was 0.800 
for a cutoff value of 2.23 pg/ml. We examined the correlation of urinary activin A with 
urinary KIM-1, urinary protein level, serum creatinine, and urinary NAG. None of these 
parameters were correlated with urinary activin A (Fig. 5C-5F).  
A significant increase in urinary activin A was observed at the acute phase of AKI, 
 but became almost undetectable at the recovery phase of AKI (Fig. 5G).  In one case 
of drug-induced AKI, urinary activin A increased in parallel with serum creatinine and 
rapidly decreased before the normalization of serum creatinine level (Fig. 5H).  
 
Urinary Activin A Level in Volume Depletion Model Mice 
To confirm that urinary activin A increases in renal AKI, we examined whether 
urinary activin A was detectable in mice with volume depletion that mimics pre-renal 
AKI.  Volume depletion significantly induced body weight reduction (Fig. 6A) and 
increased BUN levels (Fig. 6B), but not serum creatinine levels (Fig. 6C).  In contrast 
to the ischemic injury model, activin A was not present in tubular cells of the kidneys in 
volume depletion model mice (Fig. 6D).  Urinary activin A was slightly detected in mice 
with volume depletion, which was significantly lower than that in mice with AKI (Fig. 
6E). 
  
 Discussion 
In the present study, we demonstrated that urinary activin A was significantly 
increased in both ischemic mice (Fig. 3A) and AKI patients (Fig. 5A).  We also 
observed that urinary activin A was detectable in rats with ischemia-reperfusion injury 
(unpublished observation).  There are several mechanisms by which activin A could 
appear in the urine in AKI.  The first is that urinary activin A is derived from glomerular 
filtered activin A.  The molecular weight of activin A is 25 kDa, a size that can be 
theoretically filtered by glomeruli. Similar to other urinary biomarkers, including NGAL27 
or L-FABP28, glomerular filtered activin A might be reabsorbed by renal tubules through 
endocytosis in the normal kidney.  Dysfunction of tubular reabsorption might lead to 
the presence of activin A in the urine. To support this idea, urinary activin A significantly 
increased in mice with renal ischemia at 3 hr after reperfusion, at which time A subunit 
mRNA was not detected in the ischemic kidneys by in situ hybridization (Fig.1B, 
Fig.3A).  The second possible mechanism is that urinary activin A originates from 
tubular cells of the ischemic kidneys.  In situ hybridization revealed that A subunit 
mRNA for activin A was present in tubular cells of the ischemic kidneys at 6 hr after 
reperfusion and thereafter (Fig. 1B).  Consistent with this data, activin A protein was 
localized in the cytoplasm of LTL-positive tubular cells at 6 hr after reperfusion (Fig. 
1D).  At the later phase of AKI (120 hr after reperfusion), there were many activin A-
positive casts in the lumen of renal tubules (Fig. 1D).  Since activin A-producing 
tubular cells are not proliferating (Fig. 2C) or apoptotic (Fig. 2D, 2E), the mechanism 
by which activin A expression is regulated is unknown.  Nevertheless, these results 
suggest that activin A appears in the urine by tubular cell dysfunction or tubular 
damage in AKI. 
Measurement of urinary activin A has several advantages for the early diagnosis 
and treatment of AKI in the clinical setting.  We demonstrated here that activin A was 
present in proximal tubular cells of the ischemic kidneys (Fig 1C, D, E), but not in 
normal kidneys (Fig. 1C).  Activin A-positive area in ischemic kidneys increased 
according to the ischemic period (Fig. 4E).  Urinary activin A level was positively 
 correlated with the degree of activin A-positive area (Fig. 4H).   On the other hand, 
renal ischemia for 15 min did not induce the elevation of serum creatinine level (Fig. 
4C), but significantly increased urinary activin A (Fig. 4F).  In one patient with drug-
induced AKI, urinary activin A increased in parallel with serum creatinine level and 
rapidly decreased before the normalization of serum creatinine level (Fig. 5H).   
These data suggest that urinary activin A may serve as a sensitive biomarker 
reflecting the severity of tubular damage.  Urinary activin A also appears to be 
valuable in distinguishing renal and pre-renal AKI.  Similar to mice with AKI, urinary 
activin A was present in the urine of patients with renal AKI, but not in patients with pre-
renal AKI (Fig. 5A).  Although a slight increase in urinary activin A level was found in 
volume depletion model mice, its absolute value was significantly lower than that in the 
AKI mouse model (Fig. 6E).  The expression of A subunit for activin A was not 
detected in pre-renal AKI model mice by immunostaining (Fig. 6D).  Collectively, 
urinary activin A might be a beneficial marker to distinguish between renal and pre-
renal AKI according to its absolute values.   
The transition of AKI to chronic kidney disease (CKD) has major clinical 
significance.  Recent research has provided insights into the pathologic basis for 
failed recovery from AKI, such as tubular atrophy and renal fibrosis29.  Late 
upregulation of NGAL and KIM-1 could be a useful marker for sustained renal injury 
after AKI30.  Activin A acts as a potent inducer of renal fibrosis31,32, and the activin 
receptor type IIA ligand trap protects against vascular disease and renal fibrosis in 
mice with CKD33.  Given that activin A inhibits tubular regeneration of the kidney after 
renal ischemia24-26, activin A produced by tubular cells inhibits tubular regeneration in 
a paracrine manner and induces incomplete recovery from AKI.  In the present study, 
we could not clarify if the urinary activin A level reflects renal prognosis in AKI patients.  
Sustained activin A expression in the ischemic kidneys might be involved in the 
transition from AKI to CKD.   
There are several limitations in this study.  First, we have no data regarding 
urinary activin A in children with AKI.  AKI in children is associated with increased 
 mortality and prolonged hospital stay and may also be associated with long-term CKD 
development.   It has been reported that urinary activin A in infants who developed 
intraventricular hemorrhage was significantly higher than in controls at all monitoring 
time-points34.  Urinary activin A seems to be a promising tool for identifying preterm 
infants at risk of intraventricular hemorrhage.  Previous studies also demonstrated 
that urinary activin A could be detected in the urine of pregnant females with pre-
eclampsia35. Normal pregnancy urine samples had very low levels of activin A.  In 
contrast, patients with pre-eclampsia had significantly higher levels of activin A 
compared to controls.  Therefore, the advantage of urinary activin A is limited to 
patients except for infants and pregnant women.  We measured urinary activin A in 
AKI, but not in other kidney diseases.  Given that urinary activin A was increased in 
lupus-prone MRL-lpr mice36, urinary activin A might be increased in patients with other 
kidney diseases including lupus nephritis.  Further investigation will be needed to 
address this issue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Summary 
Acute kidney injury (AKI) is a common but complex condition that is associated with 
increased morbidity and mortality.  In the present study, we examined whether 
urinary activin A, a member of the TGF-beta superfamily, is present in mice with 
ischemia-reperfusion injury and in humans with AKI, as well as its potential as a 
biomarker for AKI.  Expression of activin A was markedly increased in ischemic 
mouse kidneys.  In situ hybridization demonstrated that activin mRNA was 
expressed in tubular cells of ischemic kidneys but not of normal kidneys.  
Immunoreactive activin A, which was absent in normal kidneys, was detected in the 
cytoplasm of proximal tubular cells in ischemic kidneys.  Activin A was undetectable 
in the urine of normal mice.  In contrast, activin A was significantly increased in the 
urine of ischemic mice at 3 h after reperfusion.  Urinary activin A levels increased 
according to the period of ischemia.  In humans, urinary activin A was almost 
undetectable in healthy volunteers and in patients with pre-renal AKI, but was 
significantly increased in patients with renal AKI.  There was no significant correlation 
between urinary activin A and serum activin A.  Collectively, urinary activin A might 
be a useful biomarker reflecting the severity of AKI. 
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 Figure Legends 
Figure 1 Expression of βA Subunit for Activin in the Kidneys after Renal 
Ischemia 
A: Expression of βA subunit for activin in the kidneys of mice after renal ischemia for 
25 min was examined by real-time PCR.  Values (relative expression ratio to GAPDH) 
are means ± S.E. (n=5-8).  *p<0.05, **p<0.01 vs. 0 hr.  B: Localization of βA subunit 
mRNA in the kidneys after renal ischemia was examined by in situ hybridization.  
Cortex: CO, Outer medulla: OM, Glomerular:G, Hybridization signals (blue).  AS, anti-
sense probe, S, sense probe.  Magnification: ×100 (upper panels) and ×1000 (middle, 
lower panels). C: Localization of activin A in the kidneys after renal ischemia was 
examined by immunostaining.  A subunit for activin (brown), Arrows indicate activin 
A positive renal tubules.  Magnification: ×1000.  D:Double-staining of activin A with 
nephron marker in the kidneys after renal ischemia (Upper panels are IR 6 hr, lower 
panels are IR 120 hr). A subunit for activin (red), LTL (green), DAPI (blue). 
Magnification,×1000.  Arrows indicate casts in the lumens of renal tubules. 
E: Double-staining of activin A with several nephron markers in the kidneys after renal 
ischemia (IR 48 hr).  LTL (green), THP (red), E-cadherin (red) and aquaporin 2 
(AQP2; red), and DAPI (blue).  Magnification, ×400 
 
Figure 2 Localization of A subunit for Activin, NGAL, and KIM-1 in the Kidneys 
after Renal Ischemia 
A: Localization of A subunit for activin and NGAL in the kidneys after renal ischemia 
for 25 min was examined by immunostaining.  A subunit for activin (green), NGAL 
(red).  Magnification: ×400.  B: Localization of A subunit for activin and KIM-1 in the 
kidneys after renal ischemia was examined by immunostaining.  A subunit for activin 
(green), KIM-1 (red).   Magnification: ×1000.  C: Localization of A subunit for activin 
and PCNA in the ischemic kidneys at 48 hr after reperfusion.  A subunit for activin 
(red), PCNA (green), and DAPI (blue).  Magnification: ×400.  D: Localization of A 
subunit for activin and TUNEL-positive cells in the ischemic kidneys at 48 hr after 
 reperfusion using serial sections. Positive signals (brown). Magnification: ×1000.  E: 
Localization of A subunit for activin and caspase 3-positive cells in the ischemic 
kidneys at 48 hr after reperfusion using serial sections.  Positive signals (brown), 
Magnification: ×1000. 
 
Figure 3 Urinary Activin A Level in Mice with Ischemia-reperfusion Injury 
A: Urinary activin A in mice with renal ischemia for 22 min was measured by ELISA.  
Values are means ± S.E. (n=5-11).  B, C: Correlation between urinary activin A and 
serum creatinine (B) or serum activin A (C) at 48 hr after reperfusion.  D, E: 
Correlation between urinary activin A and urinary NGAL (D) or urinary KIM-1 (E) at 48 
hr after reperfusion.  F: Correlation between serum creatinine and serum activin A at 
48 hr after reperfusion. 
 
Figure 4 Correlation of Urinary Activin A with the Severity of Kidney Damage 
A: Localization of A subunit for activin in the kidneys of mice with renal ischemia for 
15, 22, or 30 min.  The kidneys were removed for analysis at 48 hr after reperfusion.  
A subunit for activin (red), DAPI (blue).  Magnification: ×100.  B, C: BUN (B) and 
serum creatinine (C) in mice with renal ischemia at 48 hr after reperfusion.  *p<0.05, 
**p<0.01 vs. 0 hr.  D: Semiquantitative analysis of the histologic changes induced by 
renal ischemia.  ATN score was quantified as described in the Methods. *p<0.05, 
**p<0.01 vs. 15 min ischemia.  E: Quantitative analysis of positive area of A subunit 
for activin.  Five randomly selected fields of the kidneys were assessed at ×200 
magnification.  Activin A-positive area was measured using Image J software.  
Values are means ± S.E. (n=6).  **p<0.01 vs. 15 min ischemia.  F: Urinary activin A 
in mice with renal ischemia for 15, 22, or 30 min.  Urine was collected at 48 hr after 
reperfusion and urinary activin A was measured by ELISA.  Values are means ± S.E. 
(n=6).  *p<0.05 vs. 0 hr.  G, H: Correlation between activin A-positive area and ATN 
score (G) or urinary activin A (H) at 48 hr after reperfusion.  I: Correlation between 
ATN score and urinary activin A level at 48 hr after reperfusion.  
  
Figure 5 Urinary Activin A Level in Patients with Acute Kidney Injury. 
A: Urinary activin A in healthy controls (n=8), renal AKI patients (n=13) and pre-renal 
AKI patients (n=5). *p<0.05 vs. healthy controls, #p<0.05 vs pre-renal AKI patients. B: 
Urinary KIM-1 in healthy controls (n=7), renal AKI patients (n=13) and pre-renal AKI 
patients (n=5). *p<0.05 vs. healthy controls.   C-H: Correlation between urinary 
activin A and urinary KIM-1 (C), urinary protein level (D), serum creatinine (E) or urinary 
NAG (F).  G: Urinary activin A level at the acute and recovery phases of AKI (n=3).  
Data at the initial visit (acute phase) and before discharge (recovery phase) were 
shown.  H: Time course changes of urinary activin A and serum creatinine in patient 
with drug-induced AKI. 
 
Figure 6 Urinary Activin A Level in Mice with Volume Depletion 
A: Changes of body weight in the volume depletion model.  Simple volume depletion 
was induced in mice by water intake restriction to mimic pre-renal AKI.  Values are 
mean ± S.E. **p<0.01 vs. 0 hr.  B, C: Blood urea nitrogen (BUN) (B) and serum 
creatinine (C) in mice before and after 48 hr volume depletion.  Values are mean ± 
S.E. *p<0.05 vs. control (n=6).  N.S., not significant.  D: Localization of βA subunit 
for activin (red) and LTL (green) in the kidneys of volume depletion model mice was 
examined by immunostaining.  DAPI (blue).  Magnification: ×1000.  E: Urinary 
activin A level in normal mice, volume depletion (VD) model mice and I/R model mice 
(at 48 hr after reperfusion, 22 min ischemia).  *p<0.05 vs. control. #p<0.05 vs. IR. 
 
Table 1 Baseline Characteristics of AKI Patients. 
Age, sex, urinary protein level, serum creatinine, BUN, hemoglobin, WBC, platelet, 
sodium, potassium, chloride, and urinary NAG of patients with renal AKI (n=13, drug-
induced, hypercalcemia, rhabdomyolysis, and cast nephropathy) and pre-renal AKI 
(n=5, dehydration, sepsis, and shock) at the initial visit are shown.   
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Total Renal AKI Pre-renal AKI
P-value
(renal vs. pre-renal)
Number 18 13 5
Age (years) 63.3 ± 3.46 63.7 ± 4.46 62.2 ± 6.30 0.849
Sex (M/F) 10/8 6/7 4/1
U-Prot/U-Cr (g/gCr) 2.25 ± 0.55 2.91 ± 0.64 0.54 ± 0.18 0.003
sCr (mg/dl) 4.86 ± 0.50 4.96 ± 0.67 4.59 ± 0.61 0.688
BUN (mg/dl) 65.3 ± 6.22 59.8 ± 7.78 79.6 ± 7.08 0.083
Hb (g/dl) 9.31 ± 0.55 8.30 ± 0.43 11.9 ± 0.92 0.012
WBC (/μl) 5,233 ± 795.8 4,892 ± 880.0 6,120 ± 1,836 0.569
Plt (×104) 14.0 ± 2.50 13.7 ± 3.13 14.6± 4.40 0.872
Na (mEq/L) 138 ± 1.24 137± 1.30 141 ± 2.68 0.192
K (mEq/L) 4.46 ± 0.23 4.40± 0.27 4.60± 0.46 0.729
Cl (mEq/L) 103 ± 1.27 102± 1.55 106 ± 1.60 0.077
NAG (IU/L) 19.3 ± 4.30 15.1 ± 2.56 26.7 ± 10.4 0.404
Table 1 Baseline Characteristics of AKI Patients
Data collected from patients with renal AKI (drug-induced, hypercalcemia, rhabdomyolysis, and cast
nephropathy) and pre-renal AKI (dehydration, sepsis, and shock) at the initial visit are shown.
